Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an announcement.
CSPC Pharmaceutical Group Limited announced that its second marketing authorization application for Semaglutide Injection, aimed at long-term weight management in overweight adults or obese patients, has been accepted by China’s National Medical Products Administration. This product, developed by its subsidiary CSPC Baike, offers significant clinical advantages in efficacy and safety compared to existing treatments, positioning the company favorably in the competitive pharmaceutical market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on the development and production of biopharmaceutical products, with a market emphasis on innovative drugs for various health conditions.
YTD Price Performance: 65.91%
Average Trading Volume: 133,623,654
Technical Sentiment Signal: Buy
Current Market Cap: HK$88.69B
See more data about 1093 stock on TipRanks’ Stock Analysis page.